Wishart David S
Departments of Biological Science and Computing Science, University of Alberta, Edmonton, Alberta, Canada.
Drugs R D. 2008;9(5):307-22. doi: 10.2165/00126839-200809050-00002.
Metabolomics is a relatively new field of 'omics' technology that is primarily concerned with the global or system-wide characterization of small molecule metabolites using technologies such as nuclear magnetic resonance, liquid chromatography and/or mass spectrometry. Its unique focus on small molecules and the physiological effects of small molecules aligns the field of metabolomics very closely with the aims and interests of many researchers in the pharmaceutical industry. Because of its conceptual and technical overlap with many aspects of pharmaceutical research, metabolomics is now finding applications that span almost the full length of the drug discovery and development pipeline, from lead compound discovery to post-approval drug surveillance. This review explores some of the most interesting or significant applications of metabolomics as they relate to pharmaceutical research and development. Specific examples are given that show how metabolomics can be used to facilitate lead compound discovery, to improve biomarker identification (for monitoring disease status and drug efficacy) and to monitor drug metabolism and toxicity. Other applications are also discussed, including the use of metabolomics to facilitate clinical trial testing and to improve post-approval drug monitoring. These examples show that metabolomics potentially offer drug researchers and drug regulators an effective, inexpensive route to addressing many of the riskier or more expensive issues associated with the discovery, development and monitoring of drug products.
代谢组学是“组学”技术中一个相对较新的领域,主要关注利用核磁共振、液相色谱和/或质谱等技术对小分子代谢物进行整体或全系统表征。它对小分子及其生理效应的独特关注,使代谢组学领域与制药行业许多研究人员的目标和兴趣紧密契合。由于其在概念和技术上与药物研究的许多方面存在重叠,代谢组学目前正在药物发现和开发流程的几乎整个阶段找到应用,从先导化合物发现到批准后药物监测。本综述探讨了代谢组学与药物研发相关的一些最有趣或最重要的应用。文中给出了具体例子,展示了代谢组学如何用于促进先导化合物发现、改善生物标志物识别(用于监测疾病状态和药物疗效)以及监测药物代谢和毒性。还讨论了其他应用,包括利用代谢组学促进临床试验测试和改善批准后药物监测。这些例子表明,代谢组学可能为药物研究人员和药物监管机构提供一条有效、廉价的途径,以解决与药品发现、开发和监测相关的许多风险更高或成本更高的问题。